Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects with Psoriatic Arthritis.

Next Previous
Trial Profile

A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects with Psoriatic Arthritis.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perakizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions

Most Recent Events

  • 08 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
  • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 13 Oct 2011 Status changed from recruiting to active, no longer recruiting; enrollment was completed in quarter 3 of 2011 according to a Roche presentation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top